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A B S T R A C T   
Non-small cell lung carcinoma (NSCLC) is a leading cause of cancer death. Approximately one-third of patients 
with NSCLC have a KRAS mutation. KRASG12C, the most common mutation, is found in ~13% of patients. While 
KRAS was long considered ‘undruggable’, several novel direct KRASG12C inhibitors have shown encouraging 
signs of efficacy in phase I/II trials and one of these (sotorasib) has recently been approved by the US Food and 
Drug Administration. This review examines the role of KRAS mutations in NSCLC and the challenges in targeting 
KRAS. Based on specific KRAS biology, it reports exciting progress, exploring the use of novel direct KRAS in-
hibitors as monotherapy or in combination with other targeted therapies, chemotherapy, and immunotherapy.   
1. Introduction 
Lung cancer is a leading cause of cancer deaths worldwide [1]. 
Approximately 85% of lung cancers are non-small cell lung carcinomas 
(NSCLCs) [2], with the most common subtypes being lung adenocarci-
noma followed by squamous cell carcinoma [3]. Over the past 20 years, 
the treatment of advanced NSCLC has evolved from cytotoxic therapies 
that result in low response rates, rapid recurrence of disease, and short 
survival, to therapies targeting specific genomic alterations of NSCLC 
identified through molecular profiling, or immunotherapies such as 
immune checkpoint inhibitors [3]. These new therapies have led to 
survival benefits in many patients; however, the long-term survival rate 
remains very low for patients with metastatic disease [3]. A rapidly 
growing list of actionable or emerging oncogenic drivers in NSCLC in-
cludes alterations such as point mutations, insertions/deletions, ampli-
fications (e.g., EGFR, BRAF, KRAS, MET, ERBB2/HER2), or 
rearrangements (e.g., ALK, ROS1, RET, NTRK, FGFR 1/2/3, NRG1) 
[4–6]. Efficacious targeted treatments have recently emerged for pa-
tients with NSCLC driven by many of these genomic alterations. 
In contrast to most of the oncogenic drivers named above, KRAS was 
for many years considered ‘undruggable’ because of its extremely high 
affinity for GTP, a lack of well-defined hydrophobic pockets, and the 
complexity of its downstream pathways [7,8]. Accordingly, promising 
preclinical results with KRAS inhibitors in early studies failed to trans-
late into success in clinical trials [8]. The treatment landscape is now 
looking much more promising, following the recent US Food and Drug 
Administration (FDA) approval of the direct KRASG12C inhibitor sotor-
asib for adult patients with KRASG12C-mutated locally advanced or 
metastatic NSCLC, who have received at least one prior systemic therapy 
[9,10]. The accelerated approval of sotorasib was based on the favorable 
efficacy and safety results from phase I/II trials and represents the first 
approved targeted treatment for patients with a KRAS mutation 
[10–13]. Adagrasib is an investigational KRASG12C inhibitor that is also 
showing promise in phase I/II trials [14,15], with other similar drugs 
currently entering early-phase clinical trials (GDC-6036 
[NCT04449874], JDQ443 [NCT04699188], and D-1553 
[NCT04585035]) or preclinical (e.g. LY3537982, JAB-21822, BAY-293, 
and RMC-6291) testing. 
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This review examines the role of KRAS mutations in NSCLC and the 
challenges faced in targeting KRAS to date, while also exploring the 
benefits and disadvantages of novel agents that directly inhibit KRAS as 
monotherapy or that are used in combination with other targeted 
therapies, chemotherapy, and immunotherapy. 
2. KRAS mutations in NSCLC 
2.1. KRAS and oncogenesis 
KRAS is one of three isoforms of the RAS family of oncogenes, the 
most frequently mutated oncogene family in human cancers [16]. RAS 
proteins activate signaling cascades essential for cell survival, prolifer-
ation, and differentiation [17]. Approximately 86% of RAS-mutant 
cancers involve mutations in KRAS [16]. KRAS is a small GTPase that 
functions as a molecular switch, changing between an active GTP-bound 
state (‘ON’) and an inactive GDP-bound state (‘OFF’). GTP-bound KRAS 
is located on the inner face of the cell membrane, where it interacts with 
and directly activates downstream signaling pathways, in particular the 
MAPK/ERK pathway and the PI3K pathway [18,19]. Oncogenic muta-
tions in KRAS reduce its conversion from its GTP-bound to GDP-bound 
state, locking KRAS into a constitutively active form that can initiate 
intracellular cascades independent of extracellular signals. This leads to 
uncontrolled cell proliferation and survival, and contributes to tumor 
growth [20,21]. 
KRAS can have a variety of effects in cancer cells and controls complex 
signaling pathways [21]. Nevertheless, the TRACERx study demon-
strated that most KRAS mutations in patients with early-stage NSCLC 
were clonal events [22], and an analysis of a Guardant360® database 
found that the KRASG12C mutation was clonal in the majority of patients 
with NSCLC [23] (see KRAS mutation heterogeneity section); thus, its 
activation is likely an important and early event in oncogenesis. 
Furthermore, the prolonged response rate obtained with specific in-
hibitors of KRAS (see direct inhibition of KRAS section) confirm KRAS- 
dependent oncogenic addiction in this group of patients with smoking- 
related lung cancer. 
2.2. KRAS mutation prevalence and prognosis 
KRAS mutations are the most frequent molecular alteration in lung 
cancer and among the hardest to target. KRAS mutations are present in 
up to one-third of patients with NSCLC adenocarcinoma [24], although 
the prevalence may be lower in non-white populations (e.g., ~15% in 
Asians) [25]. In comparison, the frequencies of other oncogenic drivers 
in the white population are lower; e.g., ~15% for EGFR mutations 
(~35% in Asians; see Fig. 1 for the approximate prevalence of common 
oncogenic driver alterations in white patients with NSCLC adenocarci-
noma) [4,5,24]. The vast majority of KRAS mutations are in codons 12 
or 13, with a minority of mutations in codon 61 [26,27]. The most 
common KRAS mutation in NSCLC is a transversion in which the gua-
nine at codon 12 is replaced by a cysteine (G12C). The KRASG12C 
transversion accounts for ~41% of KRAS mutations in lung adenocar-
cinoma or NSCLC, equating to a presence in ~13% of patients with 
NSCLC [24]. Other mutations in KRAS include the substitutions G12A, 
G12D, G12R, G12S, G12V, G13A, C13C, G12D, G13R, G13S, and G13, 
and substitutions in G61 [27]; of these, G12V is the most common, 
occurring in ~18–20% of all KRAS-mutant NSCLC [24,28,29]. Although 
the KRAS mutational landscape seems complex, it may be more 
straightforward than for other oncogenes, as there are a finite number of 
alterations that allow opportunities for drug discovery. Additionally, the 
high frequency of KRAS mutations in patients with NSCLC justifies 
considerable molecular focus to facilitate development of new effective 
therapies. 
Whether KRAS mutations affect prognosis in NSCLC is unclear, with 
Fig. 1. Prevalence of common oncogenic driver alterations in NSCLC adenocarcinoma [4,5,24].  
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some studies reporting poorer survival outcomes in patients with KRAS 
mutations than in those with wild-type KRAS [28,30,31], and other 
studies finding no effect of KRAS mutational status on overall survival 
(OS) [32–36]. It has been reported that different KRAS variants have 
distinct patterns of tumor dissemination, with KRASG12C associated with 
more bone and brain metastases and KRASG12V associated with more 
pleural/pericardial metastases [37,38]. KRAS variants also differ his-
tologically, with KRASG12C less frequently associated with mucinous 
adenocarcinoma than KRASG12D or KRASG12V [39]. 
Most patients with KRAS-mutant NSCLC are current/former smokers 
[21] (Table S1); however, KRAS-mutant tumors can be present in pa-
tients without a history of smoking. One study found that 11.7% of 
patients who had never smoked harbored a KRAS mutation, and almost 
two-thirds of these were female [40]. This subgroup had marked genetic 
and clinical differences to the well-characterized smoker cohort; for 
example, KRASG12D was the most common mutation found in 31% of 
patients, whereas KRASG12C was found in 18.1%. Co-occurring muta-
tions were seen primarily with TP53 (35.2% of patients), with KEAP1 
and PIK3CA mutations each occurring in 4.3% of patients. Further 
characterization of the KRAS-mutant never-smoking population is 
warranted in light of new targeted therapies on the horizon. 
2.3. KRAS co-occurring mutations 
KRAS mutations are often mutually exclusive of those in other 
oncogenic drivers, which makes identification of other driver mutations 
unlikely in patients with observed KRAS mutations [41,42]. However, 
important KRAS co-occurring mutations in non-oncogenic drivers are 
relatively common [32]. One analysis found that slightly over half of 
patients with KRAS mutations had at least one additional functionally 
significant co-occurring mutation [32]. Co-occurring mutations 
observed with KRAS in NSCLC with potentially functional significant 
effects include TP53, STK11, KEAP1 MET, RBM10, EPHA5, and ERBB2/ 
HER2 (with the KRASG12C subtype only) [32,43–45]. Co-occurring mu-
tations in genes such as STK11, KEAP1, and TP53 may cooperate with 
KRAS mutations to drive oncogenesis and influence therapeutic re-
sponses, as well as the ability of tumor cells to acquire resistance 
[46–48]. Co-occurring mutations have the potential to alter prognosis, 
with STK11 and KEAP1 mutations having a proposed negative impact on 
survival [45,49]. 
2.4. KRAS mutation heterogeneity 
KRAS mutational status may be heterogeneous within a primary 
tumor, or between a primary tumor and metastases, although these 
occurrences are rare. In an analysis of KRAS-mutant tumors in NSCLC, 
some samples from individual tumors had wild-type KRAS, while other 
tumors had two different KRAS mutations [50]. Other studies in NSCLC 
have reported limited heterogeneity in KRAS mutational status within 
and between tumors [51,52], illustrating the complexity of KRAS ge-
netics. The heterogeneity in KRAS mutational status observed in NSCLC 
is also seen in other solid tumors: in metastatic colorectal cancer (CRC), 
in which ~40% of patients have a KRAS mutation [18], ~10% of pa-
tients had discordant KRAS mutational status within primary tumors 
[53] or between a primary tumor and metastases [54]. 
Another important aspect of KRAS mutation heterogeneity is clon-
ality. While somatic clonal mutations can occur in KRAS, mutations 
(including G12C) can arise as subclones [32], which act as a resistance 
mechanism to therapy [55]. In the TRACERx study, multi-region whole- 
exome sequencing was performed on 100 early-stage NSCLC tumors that 
had been resected before systemic therapy, to classify somatic mutations 
as clonal (present in all tumor cells) or subclonal (present in only a 
subset of cells) [22]. In lung adenocarcinoma, most KRAS mutations 
were found to be clonal, suggesting their emergence early in carcino-
genesis, whereas only 3/26 KRAS mutations were subclonal somatic 
events. In squamous cell carcinoma, by contrast, 2/2 mutations 
identified in KRAS were subclonal late-driver mutations [22]. However, 
as the TRACERx study focused on early-stage NSCLC (stages IA–IIIA), 
the results may not fully extrapolate to stage IV disease. Nevertheless, an 
analysis of a Guardant360® database, which included 1783 patients 
with non-squamous NSCLC, also found that the KRASG12C mutation was 
clonal (clonality >0.9) in approximately 60% of this cohort [23]. 
A recent study identified that KRASG12C-mutant tumor cells are 
heterogeneous in how they respond to KRAS inhibition at the single-cell 
level [56]. Some tumor cells, in response to suppressed MAPK output, 
produce new KRASG12C, which is maintained in its active, drug- 
insensitive state by EGFR and aurora kinase signaling [56]. Single-cell 
RNA-seq may facilitate the understanding of KRAS mutation heteroge-
neity with respect to clonality and the effects on drug resistance. 
2.5. KRAS and brain metastases 
About 20–40% of patients with NSCLC, especially adenocarcinoma, 
develop brain metastases during disease progression [26,57]. The 
limited ability of conventional treatments such as chemotherapy to 
penetrate the central nervous system (CNS) has hampered survival 
outcomes for these patients. Brain metastases are increasingly likely to 
be identified, while treatments for extracranial NSCLC continue to 
improve. Testing the CNS penetrance of the new KRAS inhibitors will be 
of importance. As third-generation EGFR and ALK inhibitors have high 
CNS penetrance [58,59], this might also be possible with KRAS 
inhibitors. 
2.6. KRAS molecular analyses 
KRAS can be detected through numerous procedures including PCR, 
Sanger sequencing or next-generation sequencing from tissue or liquid 
biopsy [60,61]. However, testing is currently often confined to clinical 
trials or academic institutions, and biomarker testing algorithms vary 
according to country and regional guidelines (reviewed in Kerr et al. 
[62]). In terms of liquid biopsy testing, non-tumor derived mutations 
that expand during clonal hematopoiesis are an important consideration 
as they can cause false positives if the results are misinterpreted [63,64]. 
However, as KRAS mutations arising from clonal hematopoiesis are rare, 
the impact on liquid biopsy testing may be minimal [63]. Laboratories 
should consider appropriate methodology and use relevant controls to 
mitigate the risk of false positives from liquid biopsy [65]. 
While the high prevalence of KRAS point mutations in NSCLC jus-
tifies significant molecular and clinical focus, it is possible that analysis 
of other KRAS-related features could be considered in the future to help 
guide clinical decision making. For example, recent data from Awad and 
colleagues demonstrated that mutant allele specific imbalances caused 
by amplification of KRASG12C may be involved in resistance to KRASG12C 
inhibitors in some patients [66]. Additionally, Nagy and colleagues 
indicated that the expression changes of genes affected by mutant KRAS 
signaling may have higher prognostic relevance than the primary 
genomic alteration itself [67]. 
3. A brief history of KRAS targeting 
KRAS-mutant NSCLC has historically proven challenging to treat, 
given the lack of advanced targeted treatments. KRAS-inhibition stra-
tegies have included reducing the proportion of active RAS-GTP, dis-
rupting protein–protein interactions, decreasing RAS at the plasma 
membrane, inhibiting downstream effector signaling, and synthetic 
lethality [7,68]. 
Despite promising preclinical/early-phase studies, KRAS drug 
development has been marked by repeated failures to translate into 
clinical success as standard of care (Table S2). Initial development 
focused on preventing RAS from associating with the cell membrane, 
e.g. by inhibiting the post-translational farnesylation of its C-terminal 
domain. However, the farnesyltransferase inhibitor tipifarnib 
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(R115777), which primarily dislodges the HRAS isoform from its 
membrane-anchoring site, showed only minimal activity in a phase II 
trial [69–71], possibly due to the predominance of KRAS mutations in 
patients with NSCLC. Salirasib, an inhibitor of all RAS isoforms, also 
showed insufficient activity in the treatment of KRAS-mutant lung 
adenocarcinoma [69]. KRAS acquired a reputation for being 
undruggable due to its picomolar affinity for GTP, relatively high cellular 
levels of GTP compared with GDP (10-fold that of GDP), and because its 
structure appears to lack a suitable hydrophobic ‘pocket’ that could 
accept a small-molecule inhibitor [16]. 
Attention turned to strategies for targeting KRAS indirectly, by 
inhibiting upstream, downstream, or parallel pathways (Table S2). 
Experimental approaches included inhibitors of signaling proteins such 
as Raf, FAK, MEK, MET, and mTOR, but were associated with relatively 
limited success [68]. 
Synthetic lethality screens have been used to identify targets that 
would theoretically result in selective death of KRAS-mutant, but not 
KRAS-wild-type, cells. One identified target has been cyclin-dependent 
kinase (CDK) 4 [72]. In the phase III JUNIPER study (patients with 
KRAS-mutant NSCLC), the CDK4 inhibitor abemaciclib did not improve 
OS compared with erlotinib, a drug recognized to perform poorly in this 
setting [73]. Additionally, a recent UK study, the National Lung Matrix 
Trial, reported that only 1/30 patients with KRAS-mutant NSCLC 
showed a response to the CDK4/6 inhibitor palbociclib [74]. Overall, 
synthetic lethality approaches may not be optimal in KRAS-mutant 
NSCLC, where pre-existing variation could result in tumors being un-
responsive to therapies targeting non-oncogene addicted pathways [75]. 
4. Direct inhibition of KRAS 
A breakthrough in the direct targeting of KRAS occurred when ad-
vances in nuclear magnetic resonance spectroscopy and X-ray crystal-
lography revealed the complete structure of the KRASG12C mutant 
protein. Ostrem and colleagues discovered a switch-II pocket allosteric 
binding site near the effector region of mutant KRASG12C, and identified 
a small molecule, ARS-1620, that could bind covalently to this pocket 
[76]. This raises the possibility of developing an allosteric inhibitor of 
mutant KRASG12C that could inhibit KRAS-dependent oncogenic 
Table 1 
KRAS inhibitors, including mode of action, development stage, and clinical results to date.  





Mode of action Development stage Clinical results 
in NSCLCto 
date 
Clinical studies       
Sotorasib [11–13,77,81] NCT03600883 
NCT04303780 
Oral G12C (KRAS 
(OFF)) 
Covalent allosteric inhibitor Phase I/II ongoing (CodeBreaK 
100) 








Adagrasib [14,15,78,82] NCT03785249 
NCT04685135 
Oral G12C (KRAS 
(OFF)) 
Covalent allosteric inhibitor Phase I/II ongoing 







GDC-6036 NCT04449874 Oral G12C Covalent allosteric inhibitor (TBC) Phase I recruiting N/A 
D-1553 NCT04585035 Oral G12C TBC Phase I/II recruiting N/A 
JDQ443 NCT04699188 Oral G12C Covalent allosteric inhibitor Phase I/II recruiting N/A 
BI-1701963 (BI-3406) NCT04111458 Oral Pan-KRAS SOS1: KRAS inhibitor that binds to the 
catalytic domain of the GEF SOS1, 
preventing interaction with KRAS-GDP 
Phase I ongoing N/A 
mRNA-5671 (V941) NCT03948763 IM G12C, 
G12D, 
G12V, G13D 
Lipid nanoparticle-formulated mRNA- 
based cancer vaccine 
Phase I ongoing, including 
NSCLC 
N/A 
Anti-KRAS engineered T- 
cell receptor therapy 
NCT01174121 IV – Gene transfer therapy Phase I/II suspended (note that 
trial enrolled patients with 
several types of solid tumors, 
but not NSCLC) 
N/A 
Preclinical studies       
LY3537982 N/A TBC G12C Covalent inhibitor Preclinical N/A 
JAB-21822 N/A TBC G12C TBC Preclinical N/A 
BAY-293 N/A TBC Pan-KRAS SOS1: KRAS inhibitor Preclinical N/A 
RMC-6291 N/A Oral G12C (KRAS 
(ON)) 
Promotes a ternary complex between 
KRAS(ON) and immunophilin cyclophilin 
A, causing steric occlusion of the effector 
face and inhibiting oncogenic signaling 
Preclinical N/A 
Tri-complex inhibitors N/A TBC G12C, 
G13C, G12D 
(KRAS(ON)) 
Promotes a ternary complex between 
KRAS(ON) and immunophilin cyclophilin 
A, causing steric occlusion of the effector 




N/A TBC   Patent registered N/A 
Tetracyclic compound [79] N/A TBC   Patent registered N/A 
KRAS-G13C inhibitor [80] N/A TBC G13C  Preclinical inhibition N/A  
a Data from patients with NSCLC in the phase II cohort of CodeBreaK 100 (NCT03600883) [13]. 
b Data from phase I/II study (NCT03785249). 
c Includes patients with unconfirmed partial responses. 
d All patients (includes NSCLC, CRC, and other tumor cohorts). DCR, disease control rate; DLT, disease-limiting toxicity; IM, intramuscular; IV, intravenous; N/A, not 
applicable; NSCLC, non-small cell lung cancer; ORR, objective response rate; TBC, to be confirmed; TRAE, treatment-related adverse event. 
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signaling without affecting signaling by wild-type KRAS. Such drugs will 
likely have lower toxicity than those targeting both wild-type and 
mutant protein. Many pharmaceutical companies are now developing 
more potent inhibitors of KRASG12C; some of these are entering clinical 
trials, while others remain in early development (Table 1) 
[11–15,77–82]. 
4.1. Sotorasib 
The first direct KRASG12C inhibitor to enter clinical testing is the 
small-molecule inhibitor sotorasib (formerly AMG 510). Analysis of the 
X-ray crystal structure of the KRASG12C–ARS-1620 covalent complex 
revealed a hidden groove in KRASG12C that becomes accessible upon 
changing the orientation of the histidine at position 95 [11,83]. A sys-
tematic effort to optimize binding to this groove led to the development 
of sotorasib, with enhanced potency over the compound ARS-1620 [83]. 
Sotorasib is an oral drug that selectively inhibits mutant KRASG12C by 
covalently and irreversibly binding to the cysteine in the KRASG12C 
transversion, locking the protein in its inactive GDP-bound state (‘OFF’) 
(Fig. 2) [78,84,85]. In preclinical testing, sotorasib inhibited ERK 
phosphorylation and tumor cell growth in multiple KRASG12C-mutant 
cell lines in vitro, and in mice with xenografts of human tumor cells 
[11,86]. Sotorasib did not affect PI3K signaling [8]. Complete regression 
of tumors was observed at higher doses, with durable cures achieved in 
8/10 mice [11]. 
Based on preclinical data, a phase I/II, first-in-human, open-label, 
multicenter trial evaluated the safety, tolerability, pharmacokinetics, 
and efficacy of sotorasib as monotherapy in heavily pretreated patients 
with locally advanced/metastatic KRASG12C solid tumors (CodeBreaK 
100; NCT03600883) [12,13,81]. The sotorasib doses for the four esca-
lation cohorts were 180 mg, 360 mg, 720 mg and 960 mg; the exposure 
to sotorasib at the 960 mg dose markedly exceeded the 90% maximal 
inhibitory concentration identified in preclinical studies indicating near 
total inhibition of KRASG12C during the dosing interval [12]. 
The phase II cohort comprised 126 patients with locally advanced/ 
metastatic KRASG12C NSCLC, who had progressed on prior standard 
therapies (81.0% had progressed on platinum-based chemotherapy plus 
PD-1/PD-L1 inhibitors); patients received oral sotorasib 960 mg once 
daily. Objective response rate (ORR) was 37.1% (including 4 [3.2%] 
patients who had a complete response), 80.6% of patients had disease 
control, and the median duration of response was 11.1 months. Median 
progression-free survival and overall survival were 6.8 and 12.5 months, 
respectively. Treatment-related adverse events (TRAEs) were reported 
in 69.8% of patients, the most common being diarrhea (31.7%), nausea 
(19.0%), alanine aminotransferase increase and aspartate aminotrans-
ferase increase (each 15.1%) [13,81]. Discontinuations due to TRAEs 
were low (7.1%); grade 3 TRAEs were reported in 19.8% of patients. One 
patient (0.8%) reported grade 4 TRAEs of pneumonitis and dyspnea; 
there were no fatal TRAEs [13,81]. Exploratory analyses demonstrated 
clinical activity of sotorasib across a range of co-occurring mutation 
profiles [13] (including patients with KEAP1 and/or STK11 co-occurring 
mutations, which may be associated with poor outcomes to therapy 
[87]). However, subgroup sample sizes were small and future prospec-
tive studies are warranted. Clinical activity was also demonstrated 
across a range of mutational allele frequencies, PD-L1 expression levels, 
and tumor mutational burden (TMB) levels [13,77]. Finally, an analysis 
of patient-reported outcome measures from CodeBreaK 100 suggested 
that sotorasib maintained or improved quality of life, physical func-
tioning, and the severity of key lung cancer-related symptoms [88]. The 
efficacy and safety data from CodeBreaK 100 supported the recent FDA 
approval of sotorasib for the treatment of patients with KRAS-mutant 
NSCLC [10]. Sotorasib has recently been added to the National 
Comprehensive Cancer Network NSCLC guidelines as a subsequent 
therapy option for patients who progressed on or after platinum-based 
chemotherapy with/without immunotherapy [89]. 
A global randomized phase III trial in NSCLC, comparing sotorasib 
daily versus standard-of-care docetaxel in second-line therapy, is 
currently ongoing (CodeBreaK 200, NCT04303780) [90]. Sotorasib is 
also currently being tested in combination with other anticancer ther-
apies (including EGFR, MEK, SHP2, pan-ErbB, mTOR, and CDK in-
hibitors, as well as immunotherapy [PD-1/PD-L1 inhibitors] and 
chemotherapy) in the CodeBreaK 101 trial in patients with advanced 
solid tumors (NCT04185883) [91]. 
Fig. 2. Targeting KRASG12C with sotorasib 
and adagrasib. A–B, The cryptic groove in 
KRASG12C targeted by sotorasib [84]. A, 
Chemical structure of sotorasib. B, crystal 
structure of KRASG12C–sotorasib complex: 
sotorasib (green) binds to the SII-P and ex-
ploits a cryptic groove formed by H95/Y96/ 
Q99. C–D, Adagrasib binds to KRASG12C [78]. 
C, Chemical structure of adagrasib. D, X-ray 
crystal structure of adagrasib bound to 
KRASG12C. Panels A–B adapted from Pantsar T 
[84], with permission from Springer Nature in 
accordance with the Creative Commons 
Attribution 4.0 International License (http 
://creativecommons.org/licenses/by/4.0/). 
Panels C–D adapted from Fell JB, et al. [78], 
with permission from the American Chemical 
Society (ACS) in accordance with the ACS 
Author Choice license (https://pubs.acs. 
org/page/policy/authorchoice_termsofuse. 
html).   
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4.2. Adagrasib 
The second small-molecule inhibitor of KRASG12C to enter clinical 
trials is adagrasib (formerly MRTX849) [14,78]. In common with 
sotorasib, adagrasib locks KRASG12C into its inactive GDP-bound form 
(‘OFF’) (Fig. 2). In preclinical studies, adagrasib inhibited cell growth in 
multiple KRASG12C cell lines, and inhibited tumor growth in vivo in mice 
bearing patient-derived xenografts, with complete tumor regression 
observed in a subset of the models [92]. Beyond KRASG12C, no single 
genomic co-alteration predicted the antitumor activity of adagrasib 
(also the case for sotorasib), but baseline gene/protein expression of 
selected members of the HER family of receptor tyrosine kinases showed 
trend associations with the magnitude of the antitumor response [14]. 
As for sotorasib, adagrasib did not affect PI3K signaling [8]. 
Adagrasib is now being tested in a phase I/II trial (KRYSTAL-1) 
involving pretreated patients with advanced solid tumors 
(NCT03785249) [15]. The doses for the escalation cohorts were 150 mg, 
300 mg, 600 mg and 1200 mg once daily, and 600 mg twice daily. The 
600 mg twice daily dose maintained adagrasib above the target plasma 
thresholds (identified in preclinical studies) throughout the 24 dosing 
interval [15]. A recent update confirmed that 79 patients had received 
adagrasib 600 mg twice daily; of the 51 patients evaluable for clinical 
activity, 45% had an objective response (includes unconfirmed partial 
responses) and 96% had disease control (median follow-up 3.6 months) 
[15]. TRAEs were identified in 85% of all patients (including the NSCLC, 
CRC, and other tumor cohorts); the most commonly reported were 
nausea (54%), diarrhea (51%), and vomiting (35%). Grade 3/4 TRAEs 
were reported in 30% of all patients, most commonly fatigue (6%), 
increased alanine aminotransferase (5%), and increase aspartate 
aminotransferase (5%). Additionally, a phase III trial (KRYSTAL-12) of 
adagrasib versus docetaxel recently began enrollment of pretreated 
patients with KRASG12C-mutated NSCLC (NCT04685135). Several 
combination clinical trials are enrolling or planned in NSCLC with afa-
tinib (NCT03785249), pembrolizumab (NCT03785249), TNO155 (SHP2 
inhibitor; NCT04330664), and palbociclib [15]. 
4.3. Other KRAS-targeted molecules 
Several other direct KRASG12C allosteric inhibitors are in the early 
stages of clinical testing as monotherapy and in combination with other 
therapies. These KRASG12C inhibitors include GDC-6036 (phase I; 
NCT04449874), D-1553 (phase I/II; NCT04585035) and JDQ443 (phase 
I/II; NCT04699188). 
Notably, all drugs that target the GDP-bound ‘OFF’ KRAS state may 
be vulnerable to resistance mutations that induce the exchange of GDP 
for GTP, or that block the GTPase activity required for the formation of 
the GDP-bound state. Researchers are, therefore, developing inhibitors 
of active GTP-bound forms (RAS(ON)) of KRASG12C, KRASG13C, and 
KRASG12D. The inhibitors use steric occlusion to prevent the target 
protein from interacting with effector proteins such as Raf, required for 
oncogenic signaling [80], and the KRASG12C ON inhibitor induced tumor 
regression in a mouse NSCLC xenograft model [80]. 
V941, a lipid nanoparticle-formulated mRNA-based cancer vaccine 
that targets four of the most commonly occurring KRAS mutations 
(G12D, G12V, G13D, and G12C), is also being developed. An ongoing 
phase I study of patients with advanced or metastatic NSCLC, CRC, or 
pancreatic adenocarcinoma is evaluating V941 alone or in combination 
with pembrolizumab (NCT03948763). 
5. Indirect inhibition of KRAS 
While the KRASG12C mutation is the most common in NSCLC, a va-
riety of other common driver mutations in KRAS can be found and may 
be more prevalent in other solid tumors. As a result, additional drugs are 
being developed that could be effective against multiple KRAS muta-
tions. These include BI-1701963, a potent and selective orally 
bioavailable SOS1:KRAS inhibitor that binds to the catalytic domain of 
the guanine nucleotide exchange factor SOS1, preventing it from 
interacting with KRAS-GDP [93]. A phase I trial of BI-1701963 in solid 
tumors is ongoing (NCT04111458). 
Encouraging results have also been obtained with inhibition of SHP2. 
SHP2 is required for complete RAS-MAPK activation, and is essential for 
KRAS-mutant carcinogenesis (Fig. 3) [94]. A SHP2 inhibitor, RMC-4630, 
has shown a reasonable safety profile and signs of clinical activity with a 
disease control rate of 67% for all KRAS mutations, and 75% for 
KRASG12C mutations, in a phase I trial in NSCLC (NCT03989115) [95]. 
In this study, 1/18 patients with KRAS mutations had a confirmed 
partial response. Preliminary data from this study also suggested that 
tolerability was improved with an intermittent dosing schedule versus 
daily dosing. Another SHP2 inhibitor, TNO155, is being studied in a 
phase I trial in advanced solid tumors, for use after disease progression 
following standard-of-care therapy (NCT03114319). This study will also 
include patients with KRASG12C-mutated NSCLC. Initial results with 
TNO155 indicated favorable pharmacokinetic properties with rapid 
absorption and a half-life of 34 h [96]. AEs were mostly grade 1/2; the 
most common grade ≥3 AEs were decreased platelets (4%), increased 
aspartate aminotransferase, diarrhea and decreased neutrophils (3% 
each) [96]. The optimal dosing schedule of TNO155 is under 
investigation. 
6. Better together: the need for combination therapy 
Even if direct inhibitors of mutant KRAS show promising efficacy in 
clinical trials, they are unlikely to provide enduring benefit if used as 
monotherapies. The activation of bypass signaling pathways, and the 
emergence of resistant subclones within previously responsive tumors as 
experienced with virtually all targeted approaches (e.g., EGFR, ALK, 
ROS1), means that combination therapies are likely to be essential. 
Targeting vertical and/or parallel pathways in addition to direct KRAS 
inhibition may be necessary to overcome both ab initio and acquired 
resistance mechanisms, and may result in more durable responses. 
To determine how cancer cells bypass inhibition to prevent complete 
tumor responses, Xue and colleagues examined the effects of direct 
KRASG12C inhibition at single-cell resolution [56]. They found that after 
treatment with a KRASG12C inhibitor, only some of the tumor cells 
remained in the inactive ‘OFF’ state, whereas others responded to the 
suppression of MAPK signaling by producing new KRASG12C proteins 
that resumed KRAS-oncogenic signaling. The new KRASG12C proteins 
were maintained in their active ‘ON’ configuration by EGFR and aurora 
kinase signaling. This flexible adaptation thus enabled a subset of cells 
within the tumor to bypass the effects of KRASG12C inhib-
ition—indicating that combination-therapy approaches, aimed at mul-
tiple targets and their associated signaling pathways (Fig. 3), will likely 
be required to achieve a longer and higher rate of response. An impor-
tant area for further consideration and research is to define patient se-
lection criteria for the different combinations. 
Toxicity is another key research area when considering combination 
therapy, and should be assessed in relation to potential additive or 
synergistic effects. Notably, recent clinical trials reported that 20.6% 
and 30% of patients had grade 3/4 toxicity when receiving monotherapy 
with sotorasib or adagrasib, respectively (toxicities were reported for 
the NSCLC and all tumor cohort in the sotorasib and adagrasib trials, 
respectively, making any comparisons challenging). Adding chemo-
therapy or combining with other targeting agents could increase 
toxicity. Overlapping toxicity profiles between treatment combinations 
need careful consideration; e.g., chemotherapy often causes gastroin-
testinal issues in patients with NSCLC [97], which may exacerbate 
gastrointestinal side effects seen in some patients treated with direct 
KRAS inhibitors. 
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6.1. Anti-KRAS agents and chemotherapy 
Chemotherapy is traditional standard-of-care for patients with 
KRAS-mutant NSCLC, but response rates have often been low and out-
comes poor [98]. The LACE meta-analysis of four randomized trials of 
adjuvant chemotherapy found that KRAS mutations did not predict OS 
in patients with resected early-stage NSCLC [34]. However, elsewhere in 
NSCLC, combining chemotherapy with direct KRAS inhibition might 
boost therapeutic responses compared with either agent alone. For 
example, combining EGFR inhibitors with chemotherapy has shown 
great promise in early clinical trials [99], and the phase III FLAURA2 
study (osimertinib with or without chemotherapy) is currently recruit-
ing (NCT04035486). Trametinib, a MEK inhibitor, has shown promising 
results in combination with chemotherapy [100]. The MEK inhibitor 
selumetinib also increased chemotherapeutic efficacy and progression- 
free survival (PFS) in a mouse model of KRASG12C NSCLC [101]. By 
contrast, the SELECT-1 randomized controlled trial of 510 patients with 
KRAS-mutant NSCLC found that adding selumetinib to docetaxel did not 
improve PFS versus docetaxel alone [102]. Preclinical evidence with 
direct KRAS inhibition plus chemotherapy has been promising, with the 
direct KRASG12C inhibitor sotorasib showing significantly increased 
tumor cell killing when combined with carboplatin in in vivo mouse 
xenograft models [11]. Sotorasib is currently being tested in combina-
tion with chemotherapy in the CodeBreaK 101 trial (NCT04185883). 
Choosing the most appropriate chemotherapy backbone could be 
critical, as subtypes of KRAS-mutant NSCLC may respond differently to 
chemotherapy regimens [103]. Subgroups could also exist even with the 
KRASG12C population, perhaps requiring further treatment modifica-
tions. Commonly used chemotherapy and chemotherapy- 
immunotherapy backbones in NSCLC include carboplatin-pemetrexed- 
pembrolizumab and platinum-pemetrexed. Chemotherapy-only 
regimens have been almost completely replaced by combinations with 
immune checkpoint inhibitors for first-line treatment. An ongoing ran-
domized phase III trial, conducted by the Netherlands Society of Pul-
monologists, is comparing bevacizumab plus chemotherapy 
(carboplatin plus paclitaxel) with cisplatin plus pemetrexed in patients 
with KRAS-mutant advanced NSCLC (NVALT 22, NCT02743923) [104]. 
6.2. Direct and indirect anti-KRAS agents 
KRAS mutations are negatively associated with response to other 
targeted therapies, potentially due to altered associations with down-
stream signaling transducers [105]. To identify the most promising 
targets for combination therapies, Misale and colleagues used high- 
throughput screening to examine the responses of a panel of KRASG12C 
NSCLC models to 112 drugs in combination with the KRASG12C inhibitor 
ARS-1620 [106]. Reactivation of the MAPK pathway and a failure to 
inactivate the PI3K-AKT pathway were identified as the mechanisms 
most likely to underlie the emergence of resistance [106]. The combi-
nation of a PI3K inhibitor plus ARS-1620 reduced tumor growth in 
patient-derived xenograft models that had shown resistance to ARS- 
1620 monotherapy, suggesting that activation of PI3K may have the 
potential to overcome resistance to KRASG12C inhibitors [106]. Consis-
tent with this, the combination of an mTOR inhibitor, an insulin-like 
growth factor 1 receptor (IGF1R) inhibitor, and ARS-1620 improved 
the effectiveness of KRAS inhibition in mutant lung cancer cells in vitro 
and in KRAS-driven mouse models [107]. 
Direct inhibitors of KRASG12C have been tested in preclinical trials in 
combination with upstream, downstream, and parallel inhibitors of 
KRAS signaling (Table 2) [11,14,80,106–110], with most studies finding 
that the response to any given combination varies between cell lines and 
models. Sotorasib, for example, was tested in vitro in combination with 
Fig. 3. Targeting KRAS-mutant tumors for the treatment of NSCLC. GAP, GTPase-activating proteins; GRB2, growth factor receptor-bound protein 2.  
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inhibitors of HER kinases, EFGR, SHP2, MEK, PI3K, and AKT [11]. 
Synergy was observed with a variety of agents, to variable degrees in 
different cell lines, but combination with a MEK inhibitor was syner-
gistic in multiple settings. The antitumor activity of a minimally effi-
cacious dose of sotorasib was also enhanced when combined with a MEK 
inhibitor in vivo, with efficacy greater than that seen with either agent 
alone. Maximal inhibition of MAPK signaling may be required for 
maximum efficacy of sotorasib [8,11]. Adagrasib was tested in combi-
nation with 70 different agents in an initial in vitro screen, before a 
subset of agents were selected for further examination [14]. In common 
with sotorasib, synergy was observed with multiple agents but varied 
between cell lines and xenograft models. Adagrasib showed maximum 
synergy with the ErbB inhibitor afatinib, followed by mTOR inhibitors 
such as vistusertib, the CDK4/6 inhibitor palbociclib, and the SHP2 in-
hibitor RMC-4550 [14]. The combination of adagrasib and TNO155 is 
being studied in advanced solid tumors in a phase I/II trial 
(NCT04330664). The combinations of GDC-6036 with erlotinib (phase I; 
NCT04449874) and JDQ443 with TNO155 (phase I/II; NCT04699188) 
are in the early stages of clinical testing. Clinical studies will need to 
evaluate whether synergistic efficacy can be achieved by combining 
KRAS inhibitors with other targeted therapies, whether toxicity profiles 
are acceptable (Table 2), and whether patient selection beyond 
KRASG12C mutational status is necessary. 
It is important to fully characterize direct KRASG12C inhibitors and 
investigate mechanisms of acquired resistance in order to inform 
combination strategies in the clinic. Recent data indicate that both 
sotorasib and adagrasib bind to the histidine (H)95 surface groove in the 
P2 pocket of KRASG12C, and models of acquired resistance may involve 
several mechanisms [111]. However, a direct comparison of resistance 
mechanisms between the two inhibitors is not yet possible [66]. One 
recent study focusing on adagrasib found that both RAS-dependent 
(KRAS alterations and amplification of KRASG12C) and non-RAS- 
dependent (acquired bypass mechanisms involving amplifications, 
activating mutations, fusions, and loss-of-function mutations in other 
genes) resistance mechanisms may be involved [66]. 
Another approach under preclinical investigation is the exploitation 
of KRAS-driven metabolic vulnerabilities in combination with other 
therapies [112]. One study found that the co-occurrence of KRAS/STK11 
mutations defined a specific subgroup of tumors with high sensitivity to 
the combination of metformin, which induced metabolic stress, and 
cisplatin [113]. Further studies are warranted to identify other sensitive 
subgroups and the optimal drug combinations for therapy. 
Finally, autophagy, a compensatory survival mechanism in tumors, 
can be activated by inhibition of the KRAS pathway [114]. Selectively 
blocking autophagy via inhibition of ULK in combination with MAPK 
pathway inhibition has shown promise in vitro [114]. Autophagy in-
hibitors could theoretically be combined with direct anti-KRAS strate-
gies; however, data from such combinations have yet to be reported. 
Table 2 
Ongoing clinical and preclinical studies examining combinations with direct and indirect targeting of KRAS and immunotherapy.  
Reference KRAS inhibitor Drugs tested Trial status/key preclinical findings Most promising 
combination(s) 
Clinical studies     
NCT04185883 
CodeBreaK 101 
Sotorasib SHP2, EGFR, pan-ErbB, mTOR, CDK, 
and MEK inhibitors; PD-1 and PD-L1 
inhibitors 
Ongoing – 
NCT04330664 Adagrasib TNO155 (SHP2 inhibitor) Ongoing – 
NCT03785249 Adagrasib Afatinib, pembrolizumab (PD-1 
inhibitor) 
Ongoing – 
NCT04111458 BI1701963 Trametinib (MEK inhibitor) Ongoing – 
NCT04449874 GDC-6036 Atezolizumab (PD-L1 inhibitor), 
cetuximab (EGFR inhibitor), 
bevacizumab (VEGF inhibitor), 
erlotinib (TKI) 
Ongoing – 
NCT04699188 JDQ443 TNO155 and spartalizumab (PD-1 
inhibitor) 
Ongoing – 
Preclinical studies     
Misale 2019 [106] ARS-1620 (KRASG12C) Tested 112 drugs in vitro, and then 
examined top candidates in vitro and in 
vivo 
Reactivation of MAPK pathway and failure to inhibit PI3K 




ARS-1620 (KRASG12C) mTOR and IGF1R inhibitor Combination of mTOR inhibitor and IGF1R inhibitor 
increased the effectiveness of ARS-1620 in KRASG12C 
mutant cells in vitro and in mouse models 
mTOR inhibitor and 
IGF1R inhibitor used 
together 
Canon 2019 [11] Sotorasib (KRASG12C) Inhibitors of HER kinases, EFGR, SHP2, 
MEK, PI3K, AKT, and anti-PD-1 
Synergy was observed with multiple agents and varied 
between cell lines, but the combination with a MEK 
inhibitor was synergistic in multiple settings. Combination 




Briere 2019 [108] Adagrasib (KRASG12C) Anti-PD-1 Combination of adagrasib and anti-PD-1 therapy enhanced 
survival over adagrasib alone 
Anti-PD-1 
Hallin 2020 [14] Adagrasib (KRASG12C) Afatinib (ErbB inhibitor), mTOR 
inhibitors (e.g., vistusertib), and CDK4/ 
6 inhibitor (palbociclib) 
Afatinib was synergistic in most of the cell lines evaluated, 
and was the top hit in a combination screen in vitro. mTOR 
inhibitors and a CDK4/6 inhibitor showed synergy with 
adagrasib in a subset of models 
ErbB inhibitor 
Ryan 2020 [109] ARS-1620 and sotorasib 
(KRASG12C) 
Inhibitors of RTKs, SHP2, and MEK/ 
ERK 
Combined KRASG12C inhibition and SHP2 inhibition 
showed the strongest synergy, with sustained RAS 
pathway suppression and improved efficacy in vitro and in 
vivo 
SHP2 inhibitor 
Hoffmann 2019  
[110] 
BI-3406 (pan-KRAS) MEK inhibitor Combination led to MAPK pathway blockade of regression 
of KRAS tumors in vitro 
MEK inhibitor 
Schulze 2019 [80] Tri-complex inhibitor of 
KRASG12C 
MEK inhibitor Submaximal concentrations of a MEK inhibitor drove 
pronounced tumor cell death in combination with the 
KRASG12C tri-complex inhibitor 
MEK inhibitor  
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6.3. Anti-KRAS agents and immunotherapy 
Generally, response to cancer immunotherapy tends to be improved 
when the tumor has a proinflammatory microenvironment, high infil-
tration of immune cells, a high mutational burden, and/or high 
expression of PD-L1 [115]. KRAS mutations in lung adenocarcinoma are 
associated with tobacco smoking, a high TMB, and an inflammatory 
tumor microenvironment with high T-cell infiltration (Fig. 4) [116]. 
Mutant KRAS has also been shown to induce the formation of immu-
nosuppressive regulatory T cells through the secretion of IL-10 and TGF- 
β1 [117]. Importantly, expression of PD-L1 is higher in KRAS-mutant 
tumors than in their wild-type counterparts [116,118–121], with me-
dian PD-L1 tumor proportion scores between 30 and 60% and 5–35% in 
patients with and without KRAS mutations, respectively [118,121]. 
Furthermore, oncogenic RAS signaling has been shown to increase PD- 
L1 expression through activation of various KRAS downstream path-
ways [122], including MAPK and STAT3 signaling [123,124], and by 
increasing phosphorylation of ERK [125]. Oncogenic RAS signaling also 
increases the stability of PD–L1 mRNA, via modulation of the AU-rich 
element-binding protein tristetraprolin [126]. Notably, one study re-
ported that patients with KRASG12C-mutant tumors have a high ORR to 
pembrolizumab monotherapy in PD-L1-positive advanced non- 
squamous NSCLC [121]. However, another study reported that ORRs 
to anti-PD-(L)1 treatment were similar in patients with KRASG12C- and 
non-KRASG12C-mutated disease [33]. 
Co-occurring mutations can also impact response to immunotherapy. 
For example, PD-L1 expression is associated with TP53 mutation in 
KRASG12C-mutant NSCLC, which correlates to a positive response to 
anti-PD-1 therapy [127]. In contrast, STK11 co-occurring mutations may 
drive resistance to PD-1/PD-L1 inhibitors in the context of KRAS-mutant 
disease [128], highlighting the complexity when developing optimal 
treatment regimens. 
Clinical trials have reported better responses to immunotherapy in 
patients with heavily pretreated NSCLC caused by KRAS mutations than 
in patients with wild-type KRAS. A meta-analysis of three studies found 
that the anti-PD-1 antibody nivolumab or anti-PD-L1 antibody atezoli-
zumab extended OS in pretreated patients with KRAS mutations but not 
in patients with wild-type KRAS [129]. In a retrospective study of pa-
tients receiving anti-PD-1/PD-L1 immunotherapy for advanced NSCLC 
with at least one oncogenic driver alteration, patients with KRAS 
mutations showed a better ORR (26%) than those with other driver 
mutations (e.g. EGFR mutations, 12%; ALK mutations, 0%) [130]. The 
same investigators reported that patients with KRAS mutations, partic-
ularly KRASG12C, seem to derive a greater benefit from immune check-
point inhibitor monotherapy than patients with other KRAS alterations 
[131]. However, there are also immunosuppressive aspects of KRAS- 
mutant tumors, which mean that immunotherapy alone has not been a 
comprehensive answer for KRAS-mutant NSCLC. For example, mutant 
KRAS is associated with the downregulation of MHC1, and production of 
immunosuppressive and protumoral cytokines (Fig. 4) [132,133]. 
Combination therapies, particularly ones that counter some of the 
immunosuppressive effects of KRAS mutations, are a rational next step. 
Accordingly, immunotherapy is being investigated for use in com-
bination with direct targeted inhibition of mutant KRAS. The long-term 
cures induced by sotorasib in mice with patient-derived xenografts 
depended on immune system engagement [11], suggesting that 
immune-checkpoint inhibition may synergize with sotorasib. Similarly, 
combined treatment with sotorasib and an anti-PD-1 inhibitor led to 
complete and durable tumor regression in 9/10 mice bearing KRASG12C- 
mutated tumors, whereas responses occurred in only 1/10 mice with 
either treatment alone. Further analysis showed that in mice with an 
intact immune system, sotorasib increased tumor infiltration by CD8+
and CD3+ T cells, as well as by macrophages and dendritic cells. Overall, 
sotorasib induced a proinflammatory tumor microenvironment, with 
increased markers of innate immune system activation as well as 
increased interferon activation, chemokine production, cytotoxic and 
natural killer cell activity, and MHC1 expression [11]. A phase I study of 
sotorasib in combination with PD-1 and PD-L1 inhibitors is ongoing 
(CodeBreaK 101, NCT04185883). 
The direct KRASG12C inhibitor adagrasib has also been shown to 
activate the immune system [108]. In mouse models of NSCLC, ada-
grasib reduced intratumoral immunosuppressive myeloid-derived sup-
pressor cell populations, and increased populations of macrophages, 
dendritic cells, and CD4+ and CD8+ T cells. In xenograft models, ada-
grasib increased MHC1 protein expression. Adagrasib in combination 
with anti-PD-1 treatment showed durable antitumor activity [108]. A 
phase Ib study of adagrasib plus pembrolizumab in patients with 
advanced solid tumors is underway (NCT03785249). Early-stage clinical 
trials are recruiting with GDC-6036 plus atezolizumab, cetuximab, or 
bevacizumab (phase I; NCT04449874), and with JDQ443 plus 
Fig. 4. Impact of KRAS-mutant tumors on the immune environment. CCL9, chemokine (C–C motif) ligand 9; CXCL3, chemokine (C-X-C motif) ligand 3; CXCR2, 
chemokine (C-X-C motif) receptor 2; GM-CSF, granulocyte–macrophage colony-stimulating factor; IL, interleukin; MDSC, myeloid-derived suppressor cell. 
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spartalizumab (phase I/II; NCT04699188). 
One challenge related to the use of immunotherapy is the potential 
for rare but serious toxicities [134]. The timing of these may be un-
predictable, sometimes emerging months after completion of immuno-
therapy (possibly due to the long half-life of antibodies [134]), which 
can impact later-line therapies [135]. If immunotherapy is to form part 
of combination approaches, appropriate sequencing of KRAS inhibitors 
and immunotherapy will be crucial. Increasing evidence suggests that 
concurrent use of immunotherapy and targeted therapies in NSCLC may 
increase the risk of adverse events [136–142]. Concurrent use of an 
EGFR tyrosine kinase inhibitor (TKI) plus immunotherapy, for example, 
was associated with relatively high rates of toxicity (including hepato-
toxicity, pyrexia, diarrhea, and interstitial lung disease) [136,141,142]. 
Additionally, an increased incidence of grade 3/4 hepatoxicity has been 
reported in patients who received immunotherapy before the ALK/ROS1 
inhibitor crizotinib (45.5%) compared with those who received crizo-
tinib alone (8%) [140]. 
It remains unclear whether the toxicity concerns for immunotherapy 
combined with EGFR TKIs and ALK inhibitors will apply to KRAS- 
targeted therapy. As EGFR TKIs and ALK inhibitors work upstream of 
the KRAS pathway, they have different toxicity profiles from the direct 
anti-KRAS agents. Currently, most patients with KRAS-mutant NSCLC 
who receive immunotherapy do so in the first-line setting, either as 
monotherapy or in combination with chemotherapy. Further investi-
gation into optimal combinations of immunotherapy with anti-KRAS 
agents is required, especially to determine whether use of an anti- 
KRAS agent before immunotherapy could improve safety and efficacy. 
Data from the IMMUNOTARGET registry study in NSCLC have sug-
gested that, in general, patients with actionable tumor alterations should 
receive targeted therapies and chemotherapy before considering 
immunotherapy as a single agent [130]. Indeed, in practice, immuno-
therapy is often discouraged in never-smokers with driver mutations 
such as EGFR, and targeted therapy is preferred. However, this approach 
cannot be translated to patients with NSCLC and KRAS mutations, many 
of whom are smokers (with a potentially increased TMB) and who may 
also respond well to immunotherapy; further investigation is warranted. 
One potential approach under investigation in a phase I clinical trial is 
the combination of a KRAS inhibitor (GDC-6036) with anti-VEGF anti-
body (bevacizumab; NCT04449874). 
7. Conclusions 
KRAS is the most commonly mutated oncogenic driver in NSCLC, 
found in approximately one-third of patients with lung adenocarcinoma; 
~13% of these harbor KRASG12C. Thus, the development of effective 
KRAS targeted therapies in NSCLC could have a positive impact on the 
largest proportion of patients compared with targeted therapies for 
other less common oncogenic drivers. Until recently, attempts to 
develop targeted therapies for KRAS-mutant NSCLC repeatedly failed. 
This changed when advances in spectroscopy and crystallography 
revealed the complete structure of the KRASG12C mutant protein, 
enabling development of direct inhibitors. One of these inhibitors 
(sotorasib) was recently approved by the FDA in patients with NSCLC, 
demonstrating that KRAS is no longer undruggable; early data on 
investigational KRASG12C inhibitors also appear promising. While 
notable advancements have been made with the development KRASG12C 
inhibitors, further studies are required to identify effective inhibitors to 
other KRAS mutants. Overall, there is a strong rationale to investigate 
combining or sequencing anti-KRAS agents with other treatment ap-
proaches, including chemotherapeutic regimens, inhibitors of signaling 
pathways upstream, downstream, or parallel to KRAS, as well as im-
mune checkpoint inhibitors. Upcoming data from clinical trials with 
KRASG12C inhibitors will inform the most promising strategies for 
achieving robust responses and better survival, limiting toxicity, and 
overcoming acquired resistance. 
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individual RAS mutations in cancer biology, Front. Oncol. 9 (2019) 1088, https:// 
doi.org/10.3389/fonc.2019.01088. 
[28] B. El Osta, M. Behera, S. Kim, L.D. Berry, G. Sica, R.N. Pillai, et al., Characteristics 
and outcomes of patients with metastatic KRAS-mutant lung adenocarcinomas: 
The Lung Cancer Mutation Consortium Experience, J. Thorac. Oncol. 14 (2019) 
876–889, https://doi.org/10.1016/j.jtho.2019.01.020. 
[29] S.V. Liu, A.M. Vanderwalde, H. Madmani, L. Raez, Y. Baca, J. Xiu, et al., 
Characterization of KRAS mutations in non-small cell lung cancer (NSCLC), 
J. Clin. Oncol. 38 (15 Suppl) (2020) 9544, https://doi.org/10.1200/ 
JCO.2020.38.15_suppl.9544. 
[30] M. Svaton, O. Fiala, M. Pesek, Z. Bortlicek, M. Minarik, L. Benesova, et al., The 
prognostic role of KRAS mutation in patients with advanced NSCLC treated with 
second- or third-line chemotherapy, Anticancer Res. 36 (2016) 1077–1082, htt 
ps://pubmed.ncbi.nlm.nih.gov/26977001/. 
[31] E. Nadal, G. Chen, J.R. Prensner, H. Shiratsuchi, C. Sam, L. Zhao, et al., KRAS- 
G12C mutation is associated with poor outcome in surgically resected lung 
adenocarcinoma, J. Thorac. Oncol. 9 (2014) 1513–1522, https://doi.org/ 
10.1097/JTO.0000000000000305. 
[32] M. Scheffler, M.A. Ihle, R. Hein, S. Merkelbach-Bruse, A.H. Scheel, 
J. Siemanowski, et al., K-ras mutation subtypes in NSCLC and associated co- 
occurring mutations in other oncogenic pathways, J. Thorac. Oncol. 14 (2019) 
606–616, https://doi.org/10.1016/j.jtho.2018.12.013. 
[33] K.C. Arbour, H. Rizvi, A. Plodkowski, D. Halpenny, M. Hellmann, G. Heller, et al., 
Clinical characteristics and anti-PD-(L)1 treatment outcomes of KRAS G12C 
mutant lung cancer compared to other molecular subtypes of KRAS-mutant lung 
cancer, J. Clin. Oncol. 38 (15 Suppl) (2020) 9596, https://doi.org/10.1200/ 
JCO.2020.38.15_suppl.9596. 
[34] F.A. Shepherd, C. Domerg, P. Hainaut, P.A. Janne, J.P. Pignon, S. Graziano, et al., 
Pooled analysis of the prognostic and predictive effects of KRAS mutation status 
and KRAS mutation subtype in early-stage resected non-small-cell lung cancer in 
four trials of adjuvant chemotherapy, J. Clin. Oncol. 31 (2013) 2173–2181, 
https://doi.org/10.1200/JCO.2012.48.1390. 
[35] L.C. Villaruz, M.A. Socinski, D.E. Cunningham, S.I. Chiosea, T.F. Burns, J. 
M. Siegfried, et al., The prognostic and predictive value of KRAS oncogene 
substitutions in lung adenocarcinoma, Cancer 119 (2013) 2268–2274, https:// 
doi.org/10.1002/cncr.28039. 
[36] W.W. Mellema, A.M. Dingemans, E. Thunnissen, P.J. Snijders, J. Derks, D. 
A. Heideman, et al., KRAS mutations in advanced nonsquamous non-small-cell 
lung cancer patients treated with first-line platinum-based chemotherapy have no 
predictive value, J. Thorac. Oncol. 8 (2013) 1190–1195, https://doi.org/ 
10.1097/JTO.0b013e318298764e. 
[37] S. Aggarwal, S. Whipple, H. Hsu, H. Tu, G. Carrigan, X. Wang, et al., 
Clinicopathological characteristics and treatment patterns observed in real-world 
care in patients with advanced non-small cell lung cancer (NSCLC) and KRAS 
G12C mutations in the Flatiron Health (FH)-Foundation Medicine (FMI) Clinico- 
Genomic Database (CGDB), Ann. Oncol. 31 (Suppl 4) (2020) S860, https://doi. 
org/10.1016/j.annonc.2020.08.1653. Abstract and associated poster 
presentation. 
[38] S. Renaud, J. Seitlinger, P.E. Falcoz, M. Schaeffer, A.C. Voegeli, M. Legrain, et al., 
Specific KRAS amino acid substitutions and EGFR mutations predict site-specific 
C.R. Lindsay et al.                                                                                                                                                                                                                              
Lung Cancer 160 (2021) 152–165
163
recurrence and metastasis following non-small-cell lung cancer surgery, Br. J. 
Cancer 115 (2016) 346–353, https://doi.org/10.1038/bjc.2016.182. 
[39] B. Lee, T. Lee, S.H. Lee, Y.L. Choi, J. Han, Clinicopathologic characteristics of 
EGFR, KRAS, and ALK alterations in 6,595 lung cancers, Oncotarget 7 (2016) 
23874–23884, https://doi.org/10.18632/oncotarget.8074. 
[40] M. Scheffler, L. Nogova, S. Michels, A. Holzem, T. Chanra, D.S.Y. Abdulla, et al., 
KRAS mutations in never-smoker NSCLC patients: Defining a new patient 
subgroup, Presented at: Deutsche Gesellschaft für Hämatologie und Medizinische 
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